Cargando…
Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
Chimeric antigen receptor T-cells (CAR-T) are now a standard approach for treating relapsed/refractory B-cell lymphomas. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a newly described entity that can manifest following CAR-T. Bone marrow (BM) aplasia i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594436/ https://www.ncbi.nlm.nih.gov/pubmed/37873752 http://dx.doi.org/10.3390/medsci11040067 |
_version_ | 1785124649407873024 |
---|---|
author | Kenkel, Troy J. Sridhar, Nithya Hammons, Lindsay R. Hintzke, Maria Shah, Nirav N. |
author_facet | Kenkel, Troy J. Sridhar, Nithya Hammons, Lindsay R. Hintzke, Maria Shah, Nirav N. |
author_sort | Kenkel, Troy J. |
collection | PubMed |
description | Chimeric antigen receptor T-cells (CAR-T) are now a standard approach for treating relapsed/refractory B-cell lymphomas. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a newly described entity that can manifest following CAR-T. Bone marrow (BM) aplasia is an uncommon manifestation of IEC-HS reported after CAR-T-cell therapy and is defined as the reduction or absence of hematopoietic progenitor cells resulting in severe pancytopenia. We describe the case of a 44-year-old female with relapsed/refractory Burkitt lymphoma (BL) who received treatment with lisocabtagene maraleucel with her post-CAR-T course complicated by cytokine release syndrome (CRS) and IEC-HS ultimately leading to persistent BM aplasia. She underwent a rescue allogeneic stem cell transplant but ultimately succumbed to progressive disease. IEC-HS is an increasingly recognized complication that occurs after CAR-T treatments that can result in aplasia, a dangerous complication with serious sequelae including infection, transfusion dependence, and high risk for hemorrhage. The underlying mechanism is poorly understood, and further studies are needed to understand how to treat it better. |
format | Online Article Text |
id | pubmed-10594436 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105944362023-10-25 Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma Kenkel, Troy J. Sridhar, Nithya Hammons, Lindsay R. Hintzke, Maria Shah, Nirav N. Med Sci (Basel) Case Report Chimeric antigen receptor T-cells (CAR-T) are now a standard approach for treating relapsed/refractory B-cell lymphomas. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a newly described entity that can manifest following CAR-T. Bone marrow (BM) aplasia is an uncommon manifestation of IEC-HS reported after CAR-T-cell therapy and is defined as the reduction or absence of hematopoietic progenitor cells resulting in severe pancytopenia. We describe the case of a 44-year-old female with relapsed/refractory Burkitt lymphoma (BL) who received treatment with lisocabtagene maraleucel with her post-CAR-T course complicated by cytokine release syndrome (CRS) and IEC-HS ultimately leading to persistent BM aplasia. She underwent a rescue allogeneic stem cell transplant but ultimately succumbed to progressive disease. IEC-HS is an increasingly recognized complication that occurs after CAR-T treatments that can result in aplasia, a dangerous complication with serious sequelae including infection, transfusion dependence, and high risk for hemorrhage. The underlying mechanism is poorly understood, and further studies are needed to understand how to treat it better. MDPI 2023-10-12 /pmc/articles/PMC10594436/ /pubmed/37873752 http://dx.doi.org/10.3390/medsci11040067 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Kenkel, Troy J. Sridhar, Nithya Hammons, Lindsay R. Hintzke, Maria Shah, Nirav N. Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma |
title | Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma |
title_full | Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma |
title_fullStr | Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma |
title_full_unstemmed | Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma |
title_short | Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma |
title_sort | bone marrow aplasia after car-t-cell therapy for relapsed/refractory burkitt’s lymphoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594436/ https://www.ncbi.nlm.nih.gov/pubmed/37873752 http://dx.doi.org/10.3390/medsci11040067 |
work_keys_str_mv | AT kenkeltroyj bonemarrowaplasiaaftercartcelltherapyforrelapsedrefractoryburkittslymphoma AT sridharnithya bonemarrowaplasiaaftercartcelltherapyforrelapsedrefractoryburkittslymphoma AT hammonslindsayr bonemarrowaplasiaaftercartcelltherapyforrelapsedrefractoryburkittslymphoma AT hintzkemaria bonemarrowaplasiaaftercartcelltherapyforrelapsedrefractoryburkittslymphoma AT shahniravn bonemarrowaplasiaaftercartcelltherapyforrelapsedrefractoryburkittslymphoma |